

Reinventing Sustainable Aquaculture & Biopharma through Insect Biotechnology

Dr. Seema Pandit¹

¹Asst. Professor, GLS University

seema.pandit@glsuniversity.ac.in

A Teaching Case Study Prepared for courses in Agribusiness Strategy, Sustainability Management, Biotechnology Commercialisation, and Social Entrepreneurship

ABSTRACT

This teaching case examines UltraNutri India Pvt. Ltd., a biotechnology startup applying Black Soldier Fly Larvae (BSFL) to address disease, antibiotic dependence, fishmeal scarcity, and waste-management challenges in Indian shrimp aquaculture. The company converts sugarcane bagasse and coffee husk into larval feedstock, induces biotic stress to enhance antimicrobial peptide expression, and formulates AMP-enriched functional feed for *Litopenaeus vannamei*. Field trials in Tamil Nadu and Andhra Pradesh reported improved survival, lower feed conversion ratios, higher harvest weights, tenfold reductions in *Vibrio* load, zero antibiotic use, and farmer profit increases ranging from 20% to 90%. The case also explores UltraNutri's second-generation platform using transgenic BSF larvae as potential expression systems for veterinary vaccines and therapeutic proteins. It ultimately presents a strategic dilemma: whether to prioritise rapid scale-up of the validated aquaculture feed business or invest in the more transformative but capital-intensive biopharma platform. The case supports discussion on sustainability, circular economy, biotechnology commercialisation, and deep-tech venture strategy.

Keywords: *Aquaculture, Insect Biotechnology, Black Soldier Fly, Hermetia illucens, Antimicrobial Peptides, Sustainable Feed, Circular Economy, Antimicrobial Resistance, Agribusiness Strategy, Social Entrepreneurship, India, Biopharma.*

Case Subject	UltraNutri India Pvt. Ltd. - Insect Biotechnology for Sustainable Aquaculture
Industry	Agribusiness, Biotechnology, Aquaculture
Location	Bangalore, India (Operations in Andhra Pradesh & Tamil Nadu)
Key Innovation	AMP-enriched Black Soldier Fly Larvae feed for shrimp farming
Impact	20-90% profit increase, 10x lower <i>Vibrio</i> loads, zero antibiotics

THE FLY THAT COULD SAVE THE SHRIMP

On a humid morning in Nellore, Andhra Pradesh, Sreenivas Rao stood at the edge of his shrimp pond and watched his livelihood die. The pond had turned toxic and unliveable for the shrimp. The shrimp were gathering at the surface, gasping. He had seen this before, the early signature of a *Vibrio* outbreak, the bacterial plague that coastal farmers across India had come to dread the way farmers elsewhere dread drought. Within days, the pond would be a graveyard of floating white bodies, and Rao would begin the familiar arithmetic of loss: how much he owed the feed supplier, how much to the hatchery, how much to the bank. In a good year, he cleared ₹ 70,000 per acre. In a disease year, he cleared nothing. And disease years, in the shrimp farming belt of coastal Andhra Pradesh,

came reliably. The industry expected to lose **25 to 30 percent** of every crop to bacterial infection, year after year, as though catastrophe were simply part of the business model.

(UltraNutri India Pvt. Ltd. - Internal introduction and technology roadmap [Unpublished internal company document], Nov-Dec-2025)

Rao's response that morning was the same as every other farmer's response on every other bad morning along this coastline. He reached for the antibiotic bottle. It was not a choice so much as a reflex. The antibiotics did not always work, and when they did, they left residues that were increasingly unwelcome in the export markets that paid the best prices for Indian shrimp. But there was nothing else to reach for.

Three hundred kilometres away, in a laboratory in Bangalore, two men were building something to reach for instead.

Dr. Nitish Sathyanarayanan, a former Prime Minister's Fellow and molecular biologist, and Matheen Sait, an operations and scale-up specialist, had been studying an insect that most people would not give a second glance: the Black Soldier Fly. It was not an obvious hero. It fed on rotting organic matter. It was unglamorous, unloved, and largely unknown outside entomological research circles. But inside its larvae, inside the very biology that allowed it to thrive in environments teeming with bacteria and pathogens, Nitish and Matheen saw something that the shrimp farming industry desperately needed: a natural, broad-spectrum antimicrobial system that no bacterium had yet learned to resist.

The insight that followed was at once scientifically elegant and commercially audacious. Black Soldier Fly larvae reared on agricultural waste like sugarcane bagasse, coffee husks that Indian farmers were currently burning. It deliberately stressed to maximise their immune response, produced Antimicrobial Peptides (AMPs) in concentrations powerful enough to suppress *Vibrio* bacteria by a factor of ten in a shrimp pond. Not reduce. Not manage. Suppress by a factor of ten, without a single gram of antibiotics, while simultaneously replacing the wild-caught fishmeal that the global ocean could no longer sustainably provide.

The company they built around this insight, *UltraNutri India Pvt. Ltd.* eventually reached Sreenivas Rao's village. A young company representative explained the science: the fly, the larvae, the peptides and Rao listened with the polite scepticism of a man who had heard many promises and paid the price of believing them. But desperation is its own form of openness, and Rao agreed to try.

His harvest weight that season nearly doubled. His profit per acre reached **₹ 2,10,000** in a year when his neighbours earned nothing. The *Vibrio* load in shrimp gut was **ten times lower** than in shrimp gut in the surrounding ponds, confirmed by laboratory analysis. He used no antibiotics at all.

(UltraNutri India Pvt. Ltd. - Internal introduction and technology roadmap [Unpublished internal company document], Nov-Dec-2025)

For Rao, the result was personal and profound: a way out of a cycle of debt, disease, and diminishing returns that had defined two generations of coastal farming in his family. For Nitish and Matheen, it was something more complicated, it was proof. And proof in the world of biotechnology startups, is not the end of the story. It is the moment the real decisions begin.

UltraNutri had demonstrated that a fly could help save the shrimp. The harder question, the one that would define the company's future and the livelihoods of thousands of farmers like Rao, was what to do next: build the feed business that could scale across India's coastline immediately, or invest in a second-generation biopharma platform that could, in time, reshape how vaccines and therapeutic proteins were produced across the developing world? The science had worked. Now came the strategy.

1.1 India's Shrimp Aquaculture Sector: A Pillar Under Pressure

India is among the world's leading producers of farmed shrimp, with the sector contributing substantially to the nation's agricultural export earnings, rural employment, and food security. The white leg shrimp, *Litopenaeus vannamei*, dominates production in the coastal states of Andhra Pradesh, Tamil Nadu, Odisha, and Gujarat. The industry supplies both domestic markets and premium export markets in the United States, Europe, and Japan; markets that have become increasingly stringent about antibiotic residues, food safety, and sustainability credentials.

Yet the structural foundations of this industry are under severe stress, and the stress operates along two parallel fault lines: disease and feed.

Challenge 1: Disease Burden	Challenge 2: Fishmeal Dependency
High biological risk in shrimp aquaculture Pathogens: <i>Vibrio parahaemolyticus</i>, <i>V. harveyi</i>, <i>V. campbellii</i>, and <i>Aeromonas</i> species Annual disease-related losses exceed USD 1 billion in India and about USD 6 billion globally 25 to 30 percent of shrimp crops lost each season Antibiotics used as preventive and curative measures, contributing to AMR and export rejections	Conventional feed depends on wild-caught fishmeal Fishmeal derived from anchovies and menhaden for protein and digestibility Over 64 percent of global fish stocks fully exploited, overexploited, or depleted India's shrimp feed industry consumes approximately 200,000 tonnes annually Prices are volatile and environmentally unsustainable

(Prasanna Kumar Patil, 2021), (Sharma, 2025) ; (UltraNutri India Pvt. Ltd. - Internal introduction and technology roadmap [Unpublished internal company document], Nov-Dec-2025)

1.2 The Global BSF Industry: Momentum Abroad, Opportunity at Home

Into this structural crisis has entered a new category of solution: insect-based feed. The Black Soldier Fly (*Hermetia illucens*, Diptera: Stratiomyidae) has attracted extraordinary scientific and commercial interest over the past decade. The global BSF industry has attracted more than USD 3.8 billion in combined private and public investment since 2014. EU regulations actively encourage BSF rearing on pre-consumer organic waste, and global insect meal production is projected to reach one million metric tonnes by 2030.

The scientific basis for this enthusiasm is well established. BSF larvae are metabolically voracious, capable of converting a wide range of organic substrates into high-quality protein and lipid biomass. Their protein profile, high in lysine, comparable in essential amino acids to soybean meal makes them nutritionally appropriate as a fishmeal replacement. Their cultivation requires significantly less land and water than conventional livestock production, and generates lower greenhouse gas and ammonia emissions per unit of protein output (Huis V. , 2013) (Oonincx, et al., 2010)

Crucially, for the purposes of UltraNutri's specific proposition, BSF larvae naturally produce a suite of Antimicrobial Peptides (AMPs) as part of their innate immune defense against the microbially rich environments in which they live and feed. These AMPs have been isolated, sequenced, and characterised in the peer-reviewed literature (Park, Kim, & Yoe, 2015) ; (Park & Yoe, 2017) (Shin, 2019). Research has demonstrated that BSF-derived AMPs act through membrane-disruption mechanisms that make the development of bacterial resistance significantly less likely than is the case with conventional antibiotics (Rodríguez-Rojas A, 2014) , (Sergey Chernysh, 2015). The AMP defensin-like peptide 4 (DLP4) , for instance, achieved 80 to 100 percent survival rates in mice infected with methicillin-resistant *Staphylococcus aureus* (MRSA) at doses of 3 to 7.5 mg/kg (Li, 2017) Cecropin-like peptide 1 (CLP1) inhibited *Escherichia coli* activity at a potency 50 times greater than ampicillin (Soon-Ik Park, 2017)

In India, however, the BSF industry faces distinct structural challenges that European and North American operators do not. The substrates most commonly used in global BSF operations namely: brewer's spent grain, food processing waste, pre-consumer organic material are already heavily competed over in the Indian context, primarily as cattle feed. There is, additionally, an absence of the regulatory incentives and sustainability premiums that drive BSF adoption in the EU. India, in the words of UltraNutri's founders, has "zero premium for sustainability" , meaning that the commercial proposition must rest entirely on demonstrable performance and cost advantages, not on certification or subsidy.

1.3 UltraNutri India Pvt. Ltd.: Company Profile

UltraNutri India Pvt. Ltd. is a Bangalore-based biotechnology startup operating at the intersection of insect science, waste valorisation, aquaculture nutrition, and biopharmaceutical innovation. The company was co-founded by Dr. Nitish Sathyanarayanan and Matheen Sait, both of whom bring complementary expertise to an enterprise of considerable scientific and commercial ambition.

Dr. Nitish Sathyanarayanan is a former Prime Minister's Fellow with a strong background in molecular biology and insect biotechnology. His scientific training has been oriented toward the applied translation of BSF biology specifically the mechanisms by which BSFL produce and express AMPs — into commercially deployable feed products. Matheen Sait is an operations and scale-up specialist, whose experience in managing the transition from laboratory innovation to large-scale manufacturing is essential to UltraNutri's growth ambitions.

The company's stated vision is "Insect Biotechnology Applications Ranging from Feed to Pharma" — a formulation that captures both the immediate commercial focus on shrimp feed (the "1st Generation" platform) and the longer-term aspiration toward biopharmaceutical applications using transgenic BSF (the "2nd Generation" platform). UltraNutri collaborates closely with ICAR-CIBA (Indian Council of Agricultural Research – Central Institute of Brackishwater Aquaculture) for feed formulation and scientific validation, and draws on an advisory board that includes faculty from Purdue University and the University of South Florida, as well as industry leaders from the biotech companies Bugworks and Eyestem. This institutional scaffolding provides both scientific credibility and strategic guidance.

2.1 The Technology Platform: Solving India's Substrate Problem

UltraNutri's first and foundational innovation was to solve the raw material problem that had blocked the Indian BSF industry from replicating European models. Rather than competing for brewer's spent grain or food waste, substrates that are already valorised as cattle feed, UltraNutri targeted agricultural residues that are otherwise discarded and, critically, environmentally harmful: sugarcane bagasse and coffee husk.

Sugarcane bagasse, the fibrous by-product of sugar extraction, is one of India's most abundant agricultural residues. Coffee husk, the outer skin of the coffee cherry, is generated in large quantities in Karnataka and Tamil Nadu. Both materials are characterised by high concentrations of lignin and cellulose, complex, recalcitrant carbohydrate structures that are indigestible by most organisms and that, when burned in open fields as currently practiced, generate greenhouse gas emissions approximately ten times greater per unit than the combustion of fossil fuels.

UltraNutri's proprietary process converts these intractable materials into a digestible, nutrient-rich substrate for BSFL rearing through a two-stage biochemical process. First, custom enzyme cocktails: specific combinations of cellulases, ligninases, and accessory enzymes are applied to break down the lignin and cellulose matrix, releasing the fermentable sugars and nitrogen compounds locked within the plant cell wall structure. Second, microbial fermentation using selected microbial consortia further conditions the substrate, detoxifying anti-nutritional factors and improving the bioavailability of key nutrients. Sugarcane bagasse provides the carbon component of the substrate; coffee husk provides the nitrogen fraction. Together, they create a balanced larval feedstock that supports vigorous larval growth while remaining entirely composed of waste streams that would otherwise be burned or discarded.

This substrate innovation is not merely technically elegant but it is strategically significant. By targeting non-competing agricultural waste streams, UltraNutri avoids the input cost pressures that have troubled other BSF operators in India and simultaneously creates a value proposition around waste valorisation that is genuinely circular: the company converts a source of pollution (open burning of crop residue) into a source of high-value nutrition.

2.2 Precision Rearing and AMP Induction: The Biotic Stress Innovation

The second pillar of UltraNutri's technology platform is the precision management of the larval rearing process itself. BSFL are raised to the sixth larval instar, the developmental stage at which protein and AMP content are at their peak under controlled conditions that have been optimised through iterative R&D in collaboration with ICAR-CIBA.

The most scientifically distinctive element of UltraNutri's rearing protocol is the deliberate induction of "biotic stress" in the developing larvae. BSF larvae naturally upregulate AMP synthesis in response to microbial challenge. When exposed to pathogens or to substrate conditions that signal microbial threat, the larvae activate innate immune signaling pathways principally the Toll pathway (responsive to Gram-positive bacteria and fungi) and the IMD (immune deficiency) pathway (responsive to Gram-negative bacteria) that drive the transcriptional upregulation of AMP genes (Chenxuan Huang, 2024) (Huang, et al., 2020) (M. D. Manniello, 2021). UltraNutri's R&D has fine-tuned the substrate composition, rearing conditions, and timing of this biotic stress exposure to maximise the expression of broad-spectrum AMPs across every production batch.

The scientific validity of this approach is supported by the peer-reviewed literature on *Hermetia illucens* immunity (Xia, Ge, & Yao, Antimicrobial peptides: An alternative to antibiotic for mitigating the risks of Antibiotic

resistance in aquaculture, 2024), (Xia, Ge, & Yao, 2021), which confirms that BSF larvae utilize the Toll-like receptor pathway to regulate AMP expression and inhibit pathogens in adverse environments. Natural AMP complexes produced by insects comprising defensins, cecropins, and dipterocins have been shown to suppress bacterial resistance development at significantly lower rates than conventional antibiotics, because the multi-component, membrane-targeting nature of AMP activity does not trigger the mutational adaptation pathways that confer antibiotic resistance (Chernysh, Gordya, & Suborova, 2015)

Laboratory validation of UltraNutri's AMP-enriched BSFL extracts has demonstrated approximately 95 percent ($\pm 4\%$) antimicrobial activity against *Vibrio parahaemolyticus* at a concentration of 1 mg/ml, with comparable efficacy demonstrated against *V. harveyi*, *V. campbellii*, and *Aeromonas* species, the primary bacterial pathogens of farmed shrimp in India. These results have been validated both in-house and at ICAR-CIBA.

2.3 Feed Formulation and the Functional Feed Concept

The processed BSFL harvested at the sixth instar using a low-moisture solid-state process that preserves the integrity of heat-sensitive AMP molecules are incorporated into a shrimp feed formulation developed in partnership with ICAR-CIBA. This formulation blends AMP-rich BSFL meal with additional nutritional components to meet the complete dietary requirements of *Litopenaeus vannamei* across its growth phases.

The conceptual innovation here deserves emphasis. Conventional fishmeal-based shrimp feed is, in the feed science literature, a nutritional commodity: it provides protein, energy, and essential amino acids, but confers no active biological function beyond these macronutrient roles. UltraNutri's BSFL-based feed is something categorically different: a functional feed. The AMPs present in the feed are ingested by the shrimp and support the animal's own innate immune response, reducing the colonisation and proliferation of *Vibrio* and other pathogens in the digestive tract and systemic circulation. This is not a passive nutritional replacement but an active biological intervention delivered through the feed itself, a distinction with profound implications for how the product is priced, communicated, and regulated.

2.4 Field Trials: Evidence from Tamil Nadu and Andhra Pradesh

(UltraNutri India Pvt. Ltd. - Internal introduction and technology roadmap [Unpublished internal company document], Nov-Dec-2025)

UltraNutri conducted field trials across two geographically and operationally distinct contexts: an individual small-scale farmer in Nagapattinam, Tamil Nadu, and a corporate-scale farming operation in Nellore, Andhra Pradesh. The results of these trials provide the evidentiary foundation for the company's commercial claims and are summarised in Exhibit 1 (see Appendices).

Nagapattinam (Individual Farmer, Disease-Outbreak Season). The Nagapattinam trial was conducted during a season characterised by a severe disease outbreak, precisely the conditions under which conventional shrimp feeds perform most poorly and under which antibiotic use escalates. Against an industry survival rate of 31 percent under these conditions, shrimp fed UltraNutri's functional feed achieved a survival rate of 36 percent, a relative improvement of approximately 16 percent in a context where every percentage point represents significant economic value. Final shrimp weight per individual reached 35 grams, compared to 31 grams in the industry standard cohort. Profit per acre for the UltraNutri farmer reached ₹ 1,45,000, compared to ₹ 70,000 for the industry standard, a doubling of net income, achieved during a disease year, without antibiotic use.

Nellore (Corporate Farmer, High-Density Stocking). The Nellore trial operated at significantly higher stocking densities: 60 to 75 shrimp per square metre, compared to conventional densities of 25 to 30 per square metre. At these densities, disease pressure is typically extreme and survival rates collapse. The industry standard in Nellore under these high-density conditions produced an 89 percent survival rate but a final harvest weight of just 7.1 grams per individual, yielding approximately 2,522 kg of shrimp per acre. The corporate farmer who completed the full trial period under conventional conditions earned effectively no profit, or operated at a loss. By contrast, the UltraNutri-fed cohort achieved a survival rate of 92 percent, a final harvest weight of 13.5 grams per individual, nearly double the industry standard and a total harvest of approximately 4,018 kg per acre. Profit per acre reached ₹. 2,10,000. RT-PCR analysis confirmed *Vibrio* load in the animal gut in the Ultranutri ponds were ten times lower than in adjacent conventional ponds.

Key Trial Outcomes at a Glance

Location	Key Achievement	Profit Impact
----------	-----------------	---------------

Nagapattinam	36% survival vs 31% industry standard during disease outbreak	₹. 1,45,000 vs ₹. 70,000
Nellore	13.5g final weight vs 7.1g at high density; 92% survival	₹ 2,10,000 vs None/Loss

(UltraNutri India Pvt. Ltd. - Internal introduction and technology roadmap [Unpublished internal company document], Nov-Dec-2025)

Across both sites, the FCR (Feed Conversion Ratio) which is a key efficiency metric indicating how many kilograms of feed are required to produce one kilogram of shrimp improved from an industry average of approximately 1.45 to 1.50 to between 1.20 and 1.30 in the UltraNutri trials. Overall farmer profitability improvements ranged from 20 percent to 90 percent across the trial dataset, with the most dramatic improvements occurring, as would be expected, in disease-affected cycles.

2.5 Business Model and Market Context

UltraNutri's business model is built around a direct performance-value proposition. In a market without a regulatory sustainability premium, where Indian shrimp farmers cannot earn more for antibiotic-free produce in the domestic market and where the export premium for sustainable certification is not yet structurally embedded, the company competes on measurable economic outcomes: higher survival rates, better FCR, higher harvest weights, and higher profit per acre.

This framing is strategically important. It means that UltraNutri must demonstrate its value not through certification or narrative but through farm-level financial outcomes. The company engages in outreach, advocacy, and technical demonstrations with farmer producer organisations (FPOs) and individual farmers, using field trial data as its primary sales tool.

The pricing challenge is significant. Indian shrimp farmers are highly cost-sensitive. The upfront cost of UltraNutri's functional feed is higher than conventional fishmeal-based feed. The company must bridge the psychological and financial gap between a higher unit cost today and a demonstrably higher net profit at harvest. This requires trust and trust in Indian aquaculture is earned through demonstrated on-farm results, not through scientific publications. The company's partnership with ICAR-CIBA, a government institution with deep credibility in the farming community, is instrumental in establishing that trust.

The competitive landscape is evolving rapidly. Global insect protein companies have begun eyeing the Indian market. Large domestic shrimp feed manufacturers, companies with deep distribution networks and established farmer relationships have the capital and incentive to develop their own insect-based offerings if the market signal becomes clear. UltraNutri's window of first-mover advantage, while currently open, will not remain open indefinitely.

2.6 The 2nd Generation Platform: Biopharma and Transgenic BSF

In parallel with the scaling of its shrimp feed business, UltraNutri has been developing a second-generation application of its BSF platform that could, if realised, represent a far more valuable and far more capital-intensive market opportunity: the use of transgenic BSF larvae as a whole-animal eukaryotic expression system for biopharmaceutical production.

The core concept draws on a well-established principle in molecular biology: eukaryotic expression systems are required for the production of biologics, vaccines, therapeutic proteins, antibodies because eukaryotic cells perform the post-translational modifications (glycosylation, folding, disulfide bond formation) necessary for these molecules to be biologically active. Conventional biopharmaceutical production uses mammalian cell culture systems (CHO cells, HEK cells) or yeast systems, which require expensive infrastructure: bioreactors, cold chains, sterile processing facilities, and complex purification trains.

UltraNutri has demonstrated, as a proof-of-concept, the ability to create transgenic BSF larvae that express a reporter protein (Green Fluorescent Protein, GFP) confirming that the genetic toolkit for larval transgenesis is functional in this species. The longer-term vision is to engineer BSF larvae to express veterinary vaccine antigens or therapeutic proteins, which could then be delivered to animals orally through the direct feeding of engineered larvae, eliminating the need for cold chains, injectable formulations, and purification facilities. The cost structure

of this approach, if successfully translated, would be substantially lower than conventional cell-culture-based bioproduction, making it particularly relevant for markets where cold-chain infrastructure is limited and vaccine distribution costs are prohibitive.

2nd Generation Innovation Highlight

Transgenic BSF larvae as whole-animal eukaryotic expression systems for veterinary vaccines and therapeutic proteins, eliminating cold chain requirements and reducing biopharmaceutical production costs.

The biopharma pipeline is, at the time of writing, at an early stage. The GFP transgenesis demonstration is a scientific milestone, not a commercial product. The path to regulatory approval for a transgenic insect-expressed veterinary vaccine in India is long and uncertain. But the scientific logic of the platform is sound, and the potential market: veterinary vaccines for shrimp, fish, poultry, and potentially human therapeutic proteins is enormous.

THE DECISION POINT

By late 2025, UltraNutri stood at a well-defined strategic crossroads. The shrimp feed business had generated compelling field trial data from Nagapattinam and Nellore. The technology platform was validated, the ICAR-CIBA partnership was productive, and early adopter farmers had demonstrated that the product delivered on its financial promise. The natural next step was to scale: to build production capacity, expand the farmer outreach network, and establish UltraNutri as the dominant supplier of functional, AMP-rich shrimp feed in the Indian market.

But scaling the feed business required capital for rearing infrastructure, substrate supply chain development, feed formulation capacity, and farmer-facing sales operations. It also required management attention, process discipline, and operational systems that a small, science-led startup was only beginning to develop.

At the same moment, the biopharma pipeline beckoned. The GFP transgenesis demonstration had attracted interest from scientific collaborators and potential investors who saw in the transgenic BSF platform a technology with global significance, a cheap, scalable, cold-chain-free biopharmaceutical production system that could address vaccine access challenges not just in Indian aquaculture but across the developing world's animal health sector. Pursuing this platform would require a different kind of capital, a longer investment horizon, and a tolerance for regulatory complexity that was categorically different from the shrimp feed business.

Dr. Nitish and Matheen faced the classic founder's dilemma of the deep-tech startup: the proven, growing, near-term revenue opportunity versus the transformative, capital-hungry, long-horizon platform play. The wrong choice could mean sacrificing either financial sustainability or long-term strategic relevance. The right choice or, more likely, the right sequencing could define not just UltraNutri's future but the structure of India's emerging bioeconomy.

The founders gathered their data, their advisors, and their conviction. The tide had turned for Sreenivas Rao. The question now was which way to direct it.

Strategic Decision Framework

UltraNutri faces the classic deep-tech dilemma: scale the proven revenue-generating feed business for near-term sustainability, or invest in the transformative but capital-intensive biopharma platform for long-term strategic value. The optimal path likely involves sequenced milestones that preserve optionality while building financial resilience.

EXHIBITS AND APPENDICES

Teaching Notes for Discussion Questions

These questions are designed to be discussed sequentially. Allow 20-25 minutes per question. Encourage students to reference specific exhibits and data points in their responses.

EXHIBIT 1: Farm-Level Financial Performance Comparison (Per Acre)

Metric	Conventional Feed (Industry Standard)	UltraNutri Feed
Stocking Density (shrimp/m ²)	25–30	60–75
Average Survival Rate	30–40% (disease-affected)	85–92%
Feed Conversion Ratio (FCR)	1.45–1.50	1.20–1.30
Average Harvest (kg)	~2,500	~4,000
Average Shrimp Price (₹/kg)	380–400	420–440
Revenue per Acre (₹.)	~9–10 lakh	~16–17 lakh
Profit per Acre (₹.)	70,000–1,00,000	1,80,000–2,10,000

(UltraNutri India Pvt. Ltd. - Internal introduction and technology roadmap [Unpublished internal company document], Nov-Dec-2025)

Figures are based on field trial outcomes in Nagapattinam (Tamil Nadu) and Nellore (Andhra Pradesh) as documented by UltraNutri India Pvt. Ltd. (2025). Outcomes are indicative and based on comparable trial conditions.

EXHIBIT 2: Comparative Field Trial Results by Site

Metric	Nagapattinam (Individual Farmer)	Nellore (Corporate Farmer)
UltraNutri Survival Rate	36% (vs. 31% Industry Standard) *	92% (vs. 89% Industry Standard)
Final Shrimp Weight	35g (vs. 31g Industry Standard)	13.5g (vs. 7.1g Industry Standard)
Average Harvest (kg)	2,500	4,018

Profit per Acre	₹. 1,45,000 (vs. ₹ 70,000)	₹ 2,10,000 (vs. None/Loss)
Profit Margin	28% (vs. 15%)	22% (vs. -0.60%)
Vibrio Load (RT-PCR)	10x lower than conventional	10x lower than conventional
FCR	1.20–1.30	1.20–1.30

Severe disease outbreak encountered during Nagapattinam trial.

(UltraNutri India Pvt. Ltd. - Internal introduction and technology roadmap [Unpublished internal company document], Nov-Dec-2025)

EXHIBIT 3: UltraNutri Technology Workflow

Stage 1: Agricultural Waste Sourcing: Sugarcane bagasse (primary carbon source) and coffee husk (nitrogen source) are sourced as zero-cost or low-cost agricultural residue streams from sugar mills and coffee processing facilities.

Stage 2 : Pre-Processing and Enzymatic Treatment: Custom enzyme cocktails catalyse the breakdown of lignin and cellulose, releasing fermentable sugars and accessible nitrogen compounds from the recalcitrant plant cell wall matrix.

Stage 3 : Microbial Fermentation: Selected microbial consortia are applied to further condition the substrate: detoxifying anti-nutritional factors, improving nutrient bioavailability, and developing the microbial community profile that will, in Stage 4, support AMP induction.

Stage 4: Precision BSFL Rearing with Biotic Stress Induction: Larvae are reared under controlled conditions to the sixth larval instar. At critical developmental windows, biotic stress is deliberately introduced to activate Toll and IMD immune signaling pathways and maximise AMP gene expression.

Stage 5: Larval Harvesting and Low-Moisture Processing: Sixth-instar larvae are harvested and processed using a low-moisture solid-state method that preserves the integrity of heat-sensitive AMP molecules while producing a shelf-stable larval meal.

Stage 6: Shrimp Feed Formulation: AMP-rich BSFL meal is blended with supplementary nutritional components, co-formulated with ICAR-CIBA, to produce the final shrimp feed product.

EXHIBIT 4: Global vs. Indian BSF Industry Landscape

Feature	Global/EU Outlook	Indian Outlook
Investment (since 2014)	>USD 3.8 billion (public + private)	Emerging sector; limited institutional support
Primary Substrates	Pre-consumer food waste, brewer's spent	Competition for brewer's spent as cattle feed
Regulatory Incentives	Strong government incentives for circular economy	Absence of sustainability premium
Industry Goal	1 million MT insect protein by 2030	Focus on localised waste valorisation
Key Differentiator	Volume and regulatory compliance	Performance and economic ROI for farmers

(Huis A. V., 2022); (The European insect sector today: Challenges, opportunities and regulatory landscape, 2024); (UltraNutri India Pvt. Ltd. - Internal introduction and technology roadmap [Unpublished internal company document]., Nov-Dec-2025)

EXHIBIT 5: SWOT Analysis — UltraNutri India Pvt. Ltd.

Strengths - Proprietary BSFL rearing and AMP-boosting technology - Demonstrated field performance in real-world disease conditions - Sustainability-driven circular business model - Credible scientific partnerships (ICAR-CIBA, Purdue University, University of South Florida) - Platform extensibility into biopharma	Weaknesses - Capital-intensive scale-up requirements - Limited market awareness and farmer familiarity with insect-based feed - Dependence on consistent agricultural waste substrate supply - Operational complexity of integrated biotech-feed manufacturing - Early-stage and pre-commercial biopharma platform
Opportunities - Rising demand for antibiotic-free aquaculture products from export markets - Fishmeal substitution demand driven by marine depletion and price volatility - Potential government support for circular economy and waste management - Expansion of BSFL platform to other aquaculture species (fish, crustaceans) - Biopharma and veterinary vaccine applications	Threats - Entry of well-capitalised domestic or international feed companies into insect protein - Regulatory uncertainty around transgenic BSF and novel biologics - Farmer price sensitivity and resistance to switching costs - Operational risks from quality inconsistency in BSFL rearing - Risk of technological imitation if process IP is insufficiently protected

EXHIBIT 6: Triple Bottom Line Impact Summary


Dimension	Impact
Environmental	Diversion of sugarcane bagasse and coffee husk from open burning; reduction in agricultural GHG emissions; decreased pressure on wild-caught fish stocks
Socio-Economic	20–90% higher farmer profits per acre; improved income resilience during disease outbreaks; rural livelihood support in coastal Andhra Pradesh and Tamil Nadu

Health	Elimination or significant reduction of antibiotic use in trial ponds; lower risk of AMR propagation in aquaculture environments; improved food safety and export compliance
Circular Economy	Agricultural waste valorised into high-value insect protein; BSFL frass utilised as organic plant growth stimulant; closed-loop resource flow

(UltraNutri India Pvt. Ltd. - Internal introduction and technology roadmap [Unpublished internal company document], Nov-Dec-2025)



Impact Model: Climate, Community, Circularity



(UltraNutri India Pvt. Ltd. - Internal introduction and technology roadmap [Unpublished internal company document], Nov-Dec-2025)

Part Two: Questions for Discussion

Question 1: What structural challenges facing Indian shrimp aquaculture does UltraNutri address, and what is the nature and extent of the evidence for its effectiveness?

This question asks students to identify, map, and evaluate the problem-solution fit at the heart of the UltraNutri case. Students should draw on Exhibits 1, 2, and 7 to distinguish between the two structural problems : disease/AMR and fishmeal dependency and assess how specifically each component of UltraNutri's technology

addresses each problem. They should be asked to evaluate the evidentiary quality of the field trial data (What are its limitations? What variables were not controlled? What additional data would a venture investor require?) and to form a judgment about the credibility of UltraNutri's performance claims.

Question 2: How does UltraNutri's "biotic stress" innovation move the product from a commodity to a specialty biotech product, and what are the strategic and pricing implications of this positioning?

This question asks students to engage with the concept of functional feed and to analyse how the AMP-induction innovation creates differentiation that is, potentially, both scientifically defensible and commercially sustainable. Students should consider: What barriers to imitation does this technological approach create? How should UltraNutri price its product in a market with no sustainability premium, and what pricing strategy best balances adoption rate and margin? How does the functional feed framing affect regulatory classification and approval pathways? The VRIO framework (Valuable, Rare, Inimitable, Organised-to-capture) may be productively applied here.

Question 3: In late 2025, UltraNutri must make a strategic resource allocation decision between scaling its shrimp feed business and accelerating investment in its biopharma platform. What do you recommend, and how would you operationalise your recommendation?

This question requires students to synthesise the entirety of the case into an actionable strategic recommendation. They must weigh the financial sustainability and market timing arguments for scaling the feed business against the scientific and commercial transformational arguments for the biopharma pivot. They should be expected to propose a sequenced strategy including resource allocation percentages, partnership structures, regulatory milestones, and go/no-go criteria and to defend their recommendation against counterarguments. Scenario planning (optimistic, base, and pessimistic cases for each pathway) is encouraged.

Part Three: The Instructor Manual

(For Instructors Only — Not for Student Distribution)

CASE SYNOPSIS

UltraNutri India Pvt. Ltd. is a Bangalore-based biotechnology startup that uses Black Soldier Fly Larvae (BSFL) to produce an AMP-enriched functional shrimp feed, addressing two structural crises in Indian aquaculture: the disease burden caused by *Vibrio* species, and the dependency on environmentally unsustainable wild-caught fishmeal. The company's proprietary technology converts indigestible agricultural waste (sugarcane bagasse and coffee husk) into optimal larval feedstock, deliberately induces "biotic stress" during larval rearing to maximise AMP expression, and produces a shrimp feed that, in field trials across Tamil Nadu and Andhra Pradesh, has achieved 10x lower *Vibrio* loads, 16 percent higher survival rates, improved FCR, and 20 to 90 percent higher farmer profits compared to conventional feeds without antibiotic use.

By late 2025, the founders face a strategic crossroads: scale the proven shrimp feed business to capture first-mover advantage in a high-growth market or allocate significant resources to a "2nd Generation" biopharma platform using transgenic BSF as a biopharmaceutical expression system, a potentially transformative but capital-intensive and long-horizon opportunity.

LEARNING OBJECTIVES

Upon completing this case, students will be able to:

Analyse the strategic logic of circular economy business models in emerging market agribusiness contexts, and evaluate how circularity is converted into competitive advantage (Bloom's: Analysis, Evaluation).

Examine the commercialisation challenges of deep-tech biotechnology in price-sensitive markets lacking regulatory sustainability premiums, and propose market entry and pricing strategies appropriate to these conditions (Bloom's: Application, Synthesis).

Evaluate the role of science-led social entrepreneurship in mitigating systemic public health risks, specifically Antimicrobial Resistance through market-based rather than regulatory mechanisms (Bloom's: Evaluation, Creation).

Apply strategic frameworks (SWOT, VRIO, Ansoff Matrix, BCG portfolio logic) to analyse a dual-platform deep-tech company's resource allocation dilemma at a critical growth inflection point (Bloom's: Application, Analysis).

Design a sequenced strategic growth plan for a sustainability-oriented startup operating at the intersection of agribusiness, biotechnology, and public health (Bloom's: Creation).

TARGET AUDIENCE AND PREREQUISITES

Primary Audience: MBA, Executive MBA, and PGDM students with an interest in agribusiness strategy, sustainability management, biotechnology commercialisation, or social entrepreneurship. The case is particularly relevant for students from South Asian agricultural or life sciences backgrounds, but the strategic and sustainability themes are globally transferable.

Secondary Audience: Advanced undergraduate BBA students with some exposure to strategy and sustainability; participants in executive development programmes in the food, agriculture, or biotech sectors.

Prerequisites: Students will benefit from prior familiarity with: (1) basic strategic frameworks (SWOT, Porter's Five Forces, VRIO); (2) introductory concepts in circular economy and sustainability management; (3) elementary understanding of biotechnology commercialisation pathways. No prior knowledge of aquaculture, entomology, or molecular biology is required; all relevant scientific concepts are explained in the case body.

RESEARCH METHODOLOGY

This case was constructed using the source materials, all provided by UltraNutri India Pvt. Ltd and various research papers cited in the references

Methodological Note: All quantitative performance data : survival rates, harvest weights, FCR values, profit per acre are drawn directly from UltraNutri's internal field trial documentation. Case writers and instructors should note that these trials were not randomised controlled experiments; they were field demonstrations conducted in collaboration with farmers and ICAR-CIBA. The data are internally consistent and scientifically plausible, but students should be encouraged to evaluate their evidentiary strength critically in the context of a business decision framework.

SUGGESTED TEACHING PLAN AND BOARD LAYOUT

Recommended Session Structure: 90 Minutes

Time	Activity	Key Focus
1–15 min	Scene Setting & Cold Call	Farmer narrative; human reality
15–40 min	Question 1 (Diagnostic)	Problem-solution fit; evidence evaluation
40–65 min	Question 2 (Analytical)	Pricing strategy; value capture
65–85 min	Question 3 (Action-Oriented)	Strategic allocation debate
85–90 min	Epilogue & Synthesis	Macro implications

Suggested Board Layout

Left panel: "The Problem" (disease burden, fishmeal dependency, key statistics). Centre panel: "The Solution" (technology workflow, AMP mechanism, field trial data). Right panel: "The Decision" (feed scale-up vs. biopharma platform — risks, rewards, sequencing options).

ANALYSIS OF DISCUSSION QUESTIONS

Question 1 Analysis

What the question is testing: Students' ability to diagnose structural problems in a sector, map them against a specific innovation, and evaluate empirical evidence critically.

Expected student insights: Strong students will recognise that UltraNutri addresses both problems simultaneously : BSFL feed replaces fishmeal (addressing feed dependency) while AMPs reduce *Vibrio* load (addressing disease burden). Weaker students will focus on one or the other. Strong students will also interrogate the trial data: the Nagapattinam trial involved a disease outbreak (making it the most compelling demonstration of AMP efficacy), but the sample is small and not randomised. The Nellore trial demonstrates exceptional profit improvement, but some of this is attributable to the unusual high-density stocking protocol, not solely to the feed.

Key teaching point: Problem-solution fit is a necessary but not sufficient condition for commercial success. The question is always: does the solution work at scale, consistently, across diverse farm conditions, and at a cost structure the market can sustain?

Question 2 Analysis

What the question is testing: Students' ability to apply strategic positioning and competitive advantage frameworks to a deep-tech product in an emerging market.

Expected student insights: Strong students will deploy the VRIO framework: UltraNutri's AMP-induction technology is Valuable (demonstrated by field trials), Rare (no Indian competitor currently replicates the biotic stress protocol), partially Inimitable in the short term (requires scientific knowhow and ICAR-CIBA collaboration), but potentially Imitable over time as the BSF sector matures. The functional feed positioning provides a pricing bridge : the product should be priced at a fraction of the proven value uplift (e.g., ₹ 30,000–50,000 per acre of value uplift shared between farmer and company), not simply at cost-plus.

Key teaching point: In markets without a regulatory sustainability premium, the product must earn its price on pure performance. The functional feed framing makes this possible but requires sustained on-farm demonstration, farmer education, and trust-building that takes time and capital.

Question 3 Analysis

What the question is testing: Students' ability to integrate financial, strategic, and ethical considerations into a coherent, defensible, and operationalisable recommendation.

Expected student insights: The most sophisticated students will resist the binary framing. Rather than choosing between "scale feed" and "accelerate biopharma," they will propose a sequenced strategy: use the next 18–24 months and near-term revenues from the feed business to fund the scientific milestones necessary to de-risk the biopharma platform (e.g., moving from GFP reporter to a first veterinary vaccine antigen, demonstrating oral delivery efficacy in shrimp, filing initial regulatory consultations). This preserves optionality while building financial sustainability.

Students should also raise the question of funding sources: the feed scale-up is financeable through impact investors, agribusiness VCs, and government schemes (BIRAC, NABARD, DST). The biopharma platform may require a different investor class: deep-tech VCs or pharma-aligned strategic partners. These capital sources are not mutually exclusive.

Key teaching point: Strategic sequencing : doing the right things in the right order is often more important than choosing between options. The question is not "which platform," but "what milestones must each platform achieve before the next investment decision point?"

EPILOGUE: WHAT HAPPENED

Current Status (Late 2025)

Field trials completed in Tamil Nadu and Andhra Pradesh

GFP transgenesis proof-of-concept demonstrated

Active fundraising phase for production scale-up

ICAR-CIBA partnership ongoing for feed and biopharma validation

As of the time of case finalisation (late 2025), UltraNutri India Pvt. Ltd. has completed its foundational field trials in Nagapattinam (Tamil Nadu) and Nellore (Andhra Pradesh), generating the performance and profitability data documented in the case. The company has demonstrated the GFP transgenesis proof-of-concept for its biopharma platform. It remains in an active fundraising phase, seeking capital to scale feed production infrastructure while protecting its scientific IP.

The founders, Dr. Nitish Sathyanarayanan and Matheen Sait, have maintained their position in the incubation ecosystem supported by the Department of Biotechnology, Government of India, and continue to develop their ICAR-CIBA partnership for both feed validation and emerging biopharma applications. The strategic resource allocation question between the feed and biopharma platforms has not been conclusively resolved. It remains the live decision that the company's leadership and investors are actively working through.

The broader context continues to evolve rapidly. Regulatory discussions around antibiotic use in Indian aquaculture are intensifying. Export market pressure from EU and US buyers for antibiotic-free and sustainably certified shrimp is increasing. The global BSF industry continues to consolidate, with European operators beginning to explore Asia-Pacific markets. For UltraNutri, the window of first-mover advantage is real but so is the clock.

The story of Sreenivas Rao and thousands of farmers like him is still being written. Whether UltraNutri's larvae will achieve the liberty its founders envision for the shrimp, for the farmers, and for the global effort to contain antimicrobial resistance depends on decisions that are yet to be made, capital that is yet to be deployed, and trust that is yet to be earned.

References

- Chenxuan Huang, C. E. (2024). Live black soldier fly (*Hermetia illucens*) larvae in feed for laying hens: effects on hen gut microbiota and behavior. *Poultry Science*, 103(3). doi:<https://doi.org/10.1016/j.psj.2024.103429>
- Chernysh, S., Gordya, N., & Suborova, T. (2015). Insect Antimicrobial Peptide Complexes Prevent Resistance Development in Bacteria. *PLOS ONE*, 10(7). doi:<https://doi.org/10.1371/journal.pone.0130788>
- Huang, C., XU, R., Liegeois, S., Chen, D., Li, Z., & Ferrandon, D. (2020). Differential requirements for mediator complex subunits in *Drosophila melanogaster* host defense against fungal and bacterial pathogens. *Frontiers in Immunology*, 11. doi:<https://doi.org/10.3389/fimmu.2020.478958>
- Huis, A. V. (2022). Edible insects: Challenges and prospects. *Entomological Research*, 52(4). doi:10.1111/1748-5967.12582
- Huis, V. (2013). Potential of insects as food and feed in assuring food security. *Annual Review of Entomology*, 563-583. Retrieved from <https://doi.org/10.1146/annurev-ento-120811-153704>
- Li, Z. M. (2017). Antibacterial and immunomodulatory activities of insect defensins-DLP2 and DLP4 against multidrug-resistant *Staphylococcus aureus*. *Scientific Reports*, 7, Article number 12124.
- M. D. Manniello, A. M. (2021). Insect antimicrobial peptides: potential weapons to counteract the antibiotic resistance. *Cellular and Molecular Life Sciences*, 78, 4259–4282. doi:<https://doi.org/10.1007/s00018-021-03784-z>

- Oonincx, D., Van Itterbee k, J., Heetkamp, M., Van den Brand, H., Van Loon, J., & Van Huis, A. (2010). An exploration on greenhouse gas and ammonia production by insect species suitable for animal or human consumption. *PLOS ONE*.
- Park, S.-I., & Yoe, S. (2017). A novel cecropin-like peptide from black soldier fly, *Hermetia illucens*: Isolation, structural and functional characterization. *Entomological Research*, 115-124. doi:<https://doi.org/10.1111/1748-5967.12215>
- Park, S.-I., Kim, J.-W., & Yoe, S. M. (2015). Purification and characterization of a novel antibacterial peptide from black soldier fly(*Hermetia Illucens*) larvae. *Developmental & Comparative Immunology*, 98-106. doi:<https://doi.org/10.1016/j.dci.2015.04.018>
- Prasanna Kumar Patil, R. G. (2021). Economic loss due to diseases in Indian shrimp farming with special reference to Enterocytozoon hepatopenaei (EHP) and white spot syndrome virus (WSSV). *Aquaculture*, 533. doi:<https://doi.org/10.1016/j.aquaculture.2020.736231>
- Rodríguez-Rojas A, M. O. (2014). Antimicrobials, Stress and Mutagenesis. . *PLoS Pathogens*, 10(10). doi:<https://doi.org/10.1371/journal.ppat.1004445>
- Sergey Chernysh, N. G. (2015). Insect Antimicrobial Peptide Complexes Prevent Resistance Development in Bacteria. *PLoS ONE*, 10(7). doi:<https://doi.org/10.1371/journal.pone.0130788>
- Sharma, R. &. (2025). *Review of the state of world marine fishery resources* . Food and Agriculture Organization of the United Nations. doi:10.4060/cd5538en
- Shin, H. S.-I. (2019). Novel attacin from *Hermetia illucens*: cDNA cloning, characterization, and antibacterial properties. *Preparative Biochemistry & Biotechnology*, 49(3), 279-285. doi: <https://doi.org/10.1080/10826068.2018.1541978>
- Soon-Ik Park, S. M. (2017). A novel cecropin-like peptide from black soldier fly, *Hermetia illucens*: Isolation, structural and functional characterization. *Entomological Research*, 47, 115-124. doi:10.1111/1748-5967.12226.
- (2024). *The European insect sector today: Challenges, opportunities and regulatory landscape*. International Platform of Insects for Food and Feed(IPIFF).
- (Nov-Dec-2025). *UltraNutri India Pvt. Ltd. - Internal introduction and technology roadmap [Unpublished internal company document]*. Bengaluru: UltraNutri India Pvt. Ltd.
- Xia, J., Ge, C., & Yao, H. (2021). Antimicrobial Peptides from Black Soldier Fly (*Hermetia illucens*) as Potential Antimicrobial Factors Representing an Alternative to Antibiotics in Livestock Farming. *Animals Basel-*, 11(7). doi:10.3390/ani11071937
- Xia, J., Ge, C., & Yao, H. (2024). Antimicrobial peptides: An alternative to antibiotic for mitigating the risks of Antibiotic resistance in aquaculture. *Environmental Research*, 251.

This case study has been prepared for educational purposes only. The data, findings, and analyses presented are grounded in documentation provided by UltraNutri India Pvt. Ltd. and peer-reviewed scientific literature as cited. The case does not constitute an endorsement of UltraNutri's products or an investment recommendation. The authors and publisher disclaim liability for any decisions made based on this material.

Keywords: *Aquaculture, Insect Biotechnology, Black Soldier Fly, Hermetia illucens, Antimicrobial Peptides, Sustainable Feed, Circular Economy, Antimicrobial Resistance, Agribusiness Strategy, Social Entrepreneurship, India, Biopharma.*